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Summary Psoriasis is a chronic, immune-mediated disorder that usually requires long-term treatment for
control. Approximately 25% of patients have moderate to severe disease and require phototherapy,
systemic therapy or both. Despite the availability of numerous therapeutic options, the long-term
management of psoriasis can be complicated by treatment-related limitations. With advances in
molecular research and technology, several biological therapies are in various stages of develop-
ment and approval for psoriasis. Biological therapies are designed to modulate key steps in the
pathogenesis of psoriasis. Collectively, biologicals have been evaluated in thousands of patients with
psoriasis and have demonstrated significant benefit with favourable safety and tolerability profiles.
The limitations of current psoriasis therapies, the value of biological therapies for psoriasis, and
guidance regarding the incorporation of biological therapies into clinical practice are discussed.
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Introduction
Psoriasis is a chronic immune-mediated disease afflict-
ing approximately 2% of the Caucasian population.1
Psoriasis can be associated with significant physical
and psychological morbidity, with an impact on
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physical and mental disability comparable with that of
other major medical illnesses such as rheumatoid
arthritis, hypertension, heart disease and depres-
sion.2, 3 Various factors limit favourable long-term
outcomes with currently available therapies, in partic-
ular their lack of consistent efficacy over time,4 the risk
of serious cumulative toxicity,5 and inconvenience.
Approximately one-quarter of all patients with
chronic plaque psoriasis require phototherapy, sys-
temic therapy or both to control their disease
adequately.6 The most frequently used systemic ther-
apies for these patients include ciclosporin, methotrex-
ate, oral retinoids and psoralen plus ultraviolet (UV) A
(PUVA),7 although the use of narrowband UVB is
gradually increasing. While not commonly used in
most countries, fumaric acid esters are widely used in
Germany, and hydroxyurea (hydroxycarbamide) and
sulfasalazine are occasionally used in certain centres.
Although the aetiology and pathogenesis of psoriasis
are not fully understood, there is substantial evidence
to support the role of the immune system, particularly
relating to the roles of T cells and cytokines.1, 8–11
Based on the continuous progress in psoriasis research
and advances in molecular biology and technology, a
new class of agents—targeted biological therapies—has
emerged.12 These biologicals are designed to block
specific molecular steps important in the pathogenesis
of psoriasis. In addition, biological therapies have been
used and are in development for other therapeutic
areas such as Crohn’s disease and rheumatoid arthri-
tis.13 Currently, three types of biologicals are approved
or are in development for psoriasis: (i) recombinant
human cytokines, (ii) monoclonal antibodies, and
(iii) fusion proteins.13 Based on current hypotheses
regarding psoriasis immunopathogenesis, two main
therapeutic approaches have emerged: modulating
either T-cell activities or cytokines (Table 1).14 Within
these main two approaches, specific strategies being
explored include reducing the number of pathogenic
T cells (e.g. CD45RO+ T cells); inhibiting T-cell
activation and trafficking; deviating the immune
response (e.g. altering the cytokine balance to favour
type 1 vs. type 2 cytokine production); and blocking
the activity of proinflammatory cytokines.13, 14
Phase I–III clinical trials conducted over the last
decade have demonstrated that biologicals provide
clinical benefit for the treatment of psoriasis. Using
internationally acknowledged safety and efficacy end-
points, the overall utility and benefit of the biologicals
has been demonstrated based on the percentage of
patients achieving at least a 50% improvement in
Psoriasis Area and Severity Index (PASI), a 75%
improvement in PASI (PASI-75), the mean change in
PASI over time, the impact of treatment on quality of
life (QOL), and safety and tolerability. In clinical trials,
efficacy is generally measured in the short term in
selected patients whereas effectiveness is considered to
be the overall effect achieved in clinical practice.
Tolerability, convenience and compliance are import-
ant factors that impact on the level of effectiveness. In
the absence of a cure for psoriasis, the optimum
therapeutic option is one that offers the best ratio
between improvement of skin lesions, and inconveni-
ence and toxicity.15
Two large patient surveys, one conducted by the
National Psoriasis Foundation (NPF) and the other by
the European Union Federation of Psoriasis Associations,
have highlighted the significant patient dissatisfaction
with currently available therapeutic options.16, 17 The
NPF survey revealed that only 18% of survey respond-
ents with severe psoriasis were currently receiving
systemic therapy; 32% of patients indicated that their
psoriasis therapy was not aggressive enough.16
With three biologicals (alefacept, efalizumab and
etanercept) approved for psoriasis in the U.S.A. and
Table 1. Biological therapies for psoriasis
Agent Phase
Agents targeting T cells or antigen-presenting cells
Alefacept Approved for psoriasis in the U.S.A.
Efalizumab (anti-CD11a) Approved for psoriasis in the U.S.A.;
submitted to the European Agency for
the Evaluation of Medicinal Products




Phase I trials for psoriasis; approved for
CD25+ cutaneous T-cell lymphoma
in the U.S.A.
Agents targeting cytokines
Infliximab (anti-TNF-a) Phase III trials for psoriasis; approved
for Crohn’s disease, RA and AS in the
U.S.A. and EU
Etanercept (anti-TNF-a) Supplemental Biologies License
Application filed in the U.S.A. for
psoriasis; approved for RA, AS,
psoriatic arthritis and juvenile chronic
arthritis in the U.S.A. and EU
Adalimumab (anti-TNF-a) Phase III trials for psoriasis; approved
for RA in the U.S.A. and EU
IL-10 Phase II




TNF, tumour necrosis factor; IL, interleukin; RA, rheumatoid arth-
ritis; AS, ankylosing spondylitis; EU, European Union.
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four biologicals (adalimumab, anakinra, etanercept
and infliximab) that collectively have been used in
rheumatology and gastroenterology in more than
700 000 patients over several years, it is appropriate
to assess the utility of biologicals in the context of daily
practice. The International Consensus Conference was
convened in order to define the current unmet medical
needs of psoriasis, to assess the value of biological
therapies in psoriasis management and to provide
general guidance regarding the use of these new
agents. Although there are variations among the
biologicals with respect to efficacy, safety and admin-
istration, the purpose of this meeting was not to
compare and contrast the individual biological therap-
ies, but rather to consider their attributes as a therapeu-
tic class. Four biologicals—alefacept, efalizumab,
etanercept and infliximab—were considered represen-
tative of the biologicals given their phase of develop-
ment (Phase III) or approval and the availability of
published data regarding their use in psoriasis.
Twenty-three dermatologists, from Argentina, Bel-
gium, Canada, Denmark, France, Germany, Greece,
Italy, the Netherlands, Norway, Spain, Sweden, Swit-
zerland, the U.K. and the U.S.A., convened for a 1-day
workshop on 21 January 2004, in Zurich, Switzerland.
The discussions facilitated by the chairman (see
Acknowledgements) during the Conference were based
primarily upon published trial data, as well as on the
personal experience of the participants. All major
aspects were discussed first in working groups and
later in a plenary session. The various consensus points
were voted upon and approved; in this manuscript,
they appear in italics, preceded by Consensus. This
manuscript was developed in accordance with these
consensus outputs.
Current systemic anti-psoriatic therapy and
unmet medical needs
Efficacy
Consensus: Current therapies effectively control symp-
toms in the short term; however, additional therapies with
favourable, long-term safety profiles are needed. As
detailed in Table 2, current therapies have good
efficacy, reducing the severity and extent of psoriasis.
However, the level of evidence for these current
therapies varies, as many were approved for psoriasis
prior to the standardization of efficacy end-points and
without the benefit of controlled clinical studies. Naldi
et al. recently highlighted the lack of standardized
assessment of efficacy.18 Among 171 studies that
assessed efficacy using a scoring system for the
severity of psoriasis, 44 different scoring systems were
used. The assessment of clinical efficacy data for
current therapies is furthermore influenced by a
number of factors, including variations in entry
criteria or baseline characteristics, varying dosages
and treatment duration, heterogeneous data, and
either inadequate or inconsistent documentation of
outcome measures.18–20
While there have been several randomized, placebo-
controlled trials that evaluated ciclosporin for psoriasis,
this is not the case for other therapies that have been
used for decades.19 The scope, design and control of
trials evaluating ciclosporin are considerably smaller19
when compared with studies involving biologicals. It is
apparent that, in addition to the published literature,
assessments of effectiveness are supported by our
extensive clinical experience with these modalities.
Despite the effectiveness of current psoriasis therapies,
there is a medical need for therapies specifically
targeted at psoriasis pathogenesis, as opposed to the
broader mechanism of action of current systemic
therapies. Furthermore, while psoriasis is a life-long
disease requiring long-term management, agents that
demonstrate rapid clinical response as well as sustained
effectiveness are desirable. Finally, given that neither
current therapies nor biologicals are curative, cure
and ⁄ or prevention remain the major unmet medical
need for psoriasis.
Safety
Consensus: The long-term safety profiles of current
therapies may limit their continuous use. These long-term
safety and tolerability profiles have not been well
documented in large, well-designed clinical trials.
Although the short-term safety profiles of these agents
have been well characterized, their long-term safety
profiles in large numbers of patients have not been
well defined in clinical trials. Reviews have demon-
strated that of the few randomized controlled trials in
psoriasis, most are short-term,18, 20 with a median
study duration of 7 weeks.18 The long-term safety
profiles of these current therapies are therefore derived
primarily from clinical experience. For example,
methotrexate has been used safely for long periods
(e.g. 10–20 years); however, no substantial documen-
tation exists from large numbers of patients.21 The
long-term use of current modalities is limited by a
number of factors, the most important of which is the
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treatment-related toxicity that restricts their ability to
be administered on a long-term basis (Table 2). Given
the risk of cumulative toxicities associated with
ciclosporin, methotrexate and various types of photo-
therapy, notably end-organ toxicity and malignancy,
guidelines have been developed in order to improve
their safety during administration and to minimize
their toxicity. For example, to minimize the risk of
nephrotoxicity associated with ciclosporin, continuous
administration beyond 1–2 years is not recommen-
ded.22 In order to detect the risk of hepatotoxicity
associated with methotrexate, liver biopsies are recom-
mended (at cumulative dose intervals of 1Æ5 g) in
addition to liver function tests.21 More recently, the
radioimmunoassay of serum levels of the aminopro-
peptide of collagen III has been recommended for
early detection of liver fibrosis in long-term metho-
trexate therapy. Although some patients are given
ciclosporin or methotrexate for prolonged periods,
many physicians and patients are hesitant to prescribe
or to continue therapy on a long-term basis.23 When
patients become intolerant of their current therapy,
develop concurrent conditions that prohibit the con-
tinuation of treatment, or reach maximum cumulative
exposure ⁄ toxicities, the selection of an alternative
therapy is often necessary.24–28 Drug–drug interac-
tions with ciclosporin and methotrexate are important
safety considerations because they limit therapeutic
options for some patients.4
Several drugs may potentiate the toxicity of methot-
rexate through a variety of mechanisms, including
alterations in protein binding, decreased renal excre-
tion of methotrexate, and synergistic hepatotoxicity.29
Ciclosporin is metabolized by the cytochrome P450 3A
system,30 the source of the majority of drug–drug
interactions.31
Treatment of different age groups
Consensus: Therapies that can be safely administered to
patients of all ages and life stages are needed. Most of
the current systemic therapeutic options are not
desirable for infants and children, who will require
long-term therapy over many decades to control their
disease. Furthermore, elderly patients with psoriasis
are likely to have concomitant illnesses and medica-
tions, which complicate therapeutic decisions. As
psoriasis presents early in life in the majority of
cases, with an equal incidence in males and females,
the therapeutic options for women of childbearing
age are extremely limited given the teratogenic effects
of some therapies, most notably methotrexate and
acitretin. Moreover, methotrexate therapy is not
advised in men planning to conceive children.
Additionally, topical therapies such as corticosteroids
may be associated with systemic toxicities (e.g.
hypothalamic–pituitary–adrenal axis suppression),
which may limit their utility.32
Monitoring
Consensus: The safety profiles of current systemic
therapies necessitate frequent or invasive monitoring;
treatments with minimal monitoring requirements are
preferable. In order to avoid the serious toxicities
associated with current therapies, frequent and ⁄ or
invasive monitoring is necessary (Table 2). Considering
the time, economics and inconvenience, these moni-
toring requirements are important to physicians and
patients alike.
Combination therapy
Consensus: Psoriasis therapies that are effective as
monotherapy and provide safe, long-term control are
needed. Given variations in effectiveness between indi-
vidual agents, variations in effectiveness over time and
the risk of treatment-related toxicity, various treatment
approaches (e.g. combination, rotational, sequential
and intermittent therapy) have evolved to address the
need for long-term control.24–28
Although ciclosporin, methotrexate and PUVA are
effective as a monotherapy, combination approaches
are often used to allow the administration of reduced
dosages in an effort to improve safety.33–35 Acitretin
monotherapy is modestly effective; therefore, it may be
combined with other therapeutic modalities, such as
PUVA, to improve efficacy.19 Topical therapies are
often added to systemic therapies or phototherapy to
reduce the dose of the systemic therapy or exposure to
phototherapy or to improve efficacy. Although combi-
ning various treatment modalities may reduce their
toxicity, it is nonetheless important to consider that
such approaches may be impractical for some patients.
Furthermore, the efficacy and safety of most combina-
tion therapies have rarely been subject to a clinical
trial.
Convenience
Consensus: Therapies that are more convenient than
current systemic treatments are needed to improve patient
8 W . S T E R R Y et al.
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compliance with treatment, thus improving therapeutic
outcomes. The convenience of a given therapeutic
approach can be affected by multiple factors, including
dosing frequency, route of administration, accessibility,
lifestyle, ability to administer monotherapy, time and
effort required, and limitations in the ability to
administer long-term treatment. While oral therapies
are simple and convenient for patients in terms of
administration, there are limitations associated with
other current therapies. For example, the inconven-
ience of topical therapies (e.g. messy, odorous, time
needed to apply) and phototherapy (e.g. limited acces-
sibility, time commitment) may reduce compliance
with the prescribed regimen. Additionally, rotating,
sequencing or combining therapies is impractical for
some patients. Thus, effective and safe long-term
therapies that could reduce the need for combining,
rotating or sequencing therapies would be expected
to improve convenience and, ultimately, overall
compliance.
Impact on quality of life
Consensus: Both the physical and psychosocial aspects
of psoriasis need to be considered and treated; assessments
need to capture physical manifestations and psychosocial
issues. In addition to assessing the ability of a given
therapy to improve psoriasis using objective measures,
it is important that the impact of treatment on QOL be
considered. Despite the well-recognized adverse impact
of psoriasis on QOL,16, 17 reviewed by Choi & Koo,36
there are few published reports regarding improve-
ments achieved with the use of current ther-
apies.18, 37 In the review of Naldi et al., a single
paper evaluated QOL.18 Some of the current therapies,
by virtue of the fact that their administration may be
impractical or associated with toxic effects, have been
shown to have a negative impact on QOL.16, 17 In
summary, given the attributes of current systemic
therapies, there is a major unmet medical need for
psoriasis therapies that safely and effectively provide
psoriasis patients with continuous control of their
disease and that have a favourable impact on their
QOL (Table 3).
The value of biological therapies for psoriasis
management
The focus of the consensus conference discussion was
based on the medicine and the science of biological
therapies; the health economic impact was not
addressed in this particular forum. Biologicals, while
a therapeutic class, differ in terms of their mechanisms
of action, and efficacy and safety profiles. Such differ-
ences will become important when selecting the
appropriate therapy for patients on an individual basis.
It was the overall value of biologicals that was
discussed collectively during this meeting.
Efficacy
Consensus: As a therapeutic class, biologicals are effective
for the treatment of psoriasis. There is robust evidence
from multiple, large, well-designed, randomized, pla-
cebo-controlled trials of biological therapies for psori-
asis (Table 4). Entry criteria for the trials evaluating
biologicals for psoriasis varied slightly from study to
study but generally included involvement of at least
5%38)10% body surface area39–41 and a minimal PASI
response of 1041 to 12 points.40 All of the trials for
each of these agents met their primary end-points, with
a significantly greater proportion of patients who
received the biological therapy achieving a PASI-75
response compared with those patients who received
placebo (Table 4). Efalizumab, etanercept and infliximab
are associated with early clinical response, within
4 weeks of initiating treatment.
Safety
Consensus: Biologicals have been proven relatively safe in
the short to intermediate term; longer-term safety and
efficacy outcomes will need to continue to be observed and
accumulated. Biologicals have proven to be relatively
Table 3. Consensus: unmet medical needs for psoriasis treatment
Efficacy
1 Curative (highly desirable, but not within sight at present)
2 Specifically targeted at psoriasis pathogenesis, as opposed to the
broader mechanism of action of current systemic therapies
3 Providing rapid clinical response
4 Administered on a long-term basis to allow continuous
disease control
5 Effective as monotherapy
Safety
1 Safe during chronic treatment, allowing prolonged
or unlimited use
2 Requires minimal monitoring
3 Addresses needs in various life stages (e.g. infants and
children, child-bearing ⁄ conceiving age, and elderly)
4 Minimal drug–drug interactions
5 Minimal disease contraindications
Convenience
1 Convenient and well accepted by patients
2 Easily administered
B I O L O G I C A L T H E R A P I E S I N T H E S Y S T E M I C M A N A G E M E N T O F P S O R I A S I S 9
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safe during short- and intermediate-term administra-
tion (Table 4). The short-term adverse events are
mostly benign (e.g. acute influenza-like symptoms
upon initiating therapy), but serious infusion reactions
may rarely occur. Biological therapies do not appear to
show any evidence of hepatotoxicity or nephrotoxicity.
Efalizumab and alefacept have been evaluated in
patients with psoriasis for periods of 2–4Æ5 years.42, 43
Data available for up to 24 months of continuous
efalizumab therapy and up to nine cycles of alefacept
therapy indicate that, in addition to sustained efficacy,
there is no increase in toxicity over time.42–44 Rare
cases (0Æ3%) of reversible thrombocytopenia have been
observed in efalizumab-treated patients during clinical
trials.45 During alefacept therapy, memory T-cell
counts are reduced as a likely consequence of the
mechanism of alefacept action, with no significant
reduction noted over multiple courses of therapy.46 A
12-week course of alefacept did not impair primary or
secondary antibody responses to a neoantigen, or
memory responses to a recall antigen.47
There are considerable longer-term safety data for
etanercept and infliximab used for diseases other than
psoriasis, where they have been proven to be relatively
safe therapeutic approaches in the majority of patients.
There are several potential concerns with anti-tumour
necrosis factor (TNF)-a therapies that have been
observed in small numbers of patients with Crohn’s
disease or rheumatoid arthritis, including infections,
antinuclear antibody formation,48 drug-induced auto-
immune disorders (e.g. drug-induced lupus erythema-
tosus),49, 50 heart failure51 and nervous system
disorders (including demyelinating disorders), as well
as serious infusion reactions.52 Long-term data in
psoriasis patients will be required to define clearly the
long-term safety of these therapies in patients with
psoriasis.
The primary concern regarding long-term safety of
biologicals relates to the risk of immunosuppression,
the level of which may be related to the development of
infection or malignancy.53 Although cases of lym-
phoma in patients with rheumatoid arthritis receiving
TNF-a inhibitors have been reported, a clear causal
relationship has not been established;54 the Arthritis
Advisory Committee of the US Food and Drug Admin-
istration concluded that causality of lymphoma in
these patients could not be established with certainty. It
has been suggested that the rate of lymphoma in
patients with psoriasis who are 65 years or older is
threefold the rate observed in patients without psori-
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baseline rate of lymphoma in this patient population in
order to accurately assess the risk of lymphoprolifera-
tive diseases associated with immunosuppressive ther-
apies.55 Patients who are receiving monoclonal
antibody anti-TNF-a therapy are at increased risk of
developing infection, specifically active tuberculo-
sis.56, 57 Although there may be variations in risk
among the different anti-TNF-a inhibitors, the potential
risk needs to be considered, as cases have been reported
in patients receiving infliximab, etanercept and adal-
imumab.56, 58 To be cautious and to minimize the risk,
a tuberculin skin test should be performed prior to
initiating anti-TNF-a therapy using monoclonal anti-
bodies, with chest radiography as indicated.56, 59
Although it will be important to understand the
impact of these biological therapies on the immune
system in the long term and in a larger number of
patients with psoriasis, the data to date in other patient
populations (e.g. rheumatology, Crohn’s disease) are
reassuring.60, 61 However, until the impact is more
clearly defined, psoriasis patients treated with biolog-
icals should be carefully observed.
Biological therapeutics are not metabolized by the
cytochrome P450 system; thus, there are no pharma-
cokinetic drug interactions. Although formal drug
interaction studies have not yet been performed, there
is no evidence to suggest that biologicals are limited by
drug–drug interactions (Table 4). There are fewer
disease contraindications for biological therapies than
for current systemic therapies (Table 4). Thus, biologi-
cal therapies may be appropriate for a broader range of
patients than are the current systemic therapies; these
issues are being explored further in pilot studies in
small numbers of patients.
Monitoring and convenience
Consensus: There are fewer monitoring requirements for
biological therapies than for current systemic ther-
apies. Compared with the monitoring requirements
for current systemic therapies, there are fewer monit-
oring requirements prior to initiating and during
biological therapy (Table 4). Monitoring requirements
for the biological therapies vary among the individual
agents, and the recommendations contained within the
prescribing information should be followed. Studies
have demonstrated that despite the fact that biologicals
are injectable, most patients are comfortable with such
administration and it does not adversely impact their
QOL.62, 63 Furthermore, the ability of patients to self-
administer many of the biological agents at home
obviates the need for frequent visits to the clinic, and
particularly for extensive disease, allows severe psori-
asis to be managed on an out-patient basis.
Monotherapy and combination therapy with biologicals
Consensus: Biological therapies are comparably or more
effective than current therapies when administered as
monotherapy. All biological therapies met their primary
efficacy end-point when administered as monotherapy
in randomized, placebo-controlled trials. There are
relatively few published data regarding the safety of
combination therapy with biologicals; however, evi-
dence to date does not indicate that biological therapies
exacerbate the toxicity of other psoriasis ther-
apies.48, 64 Trials of biologicals in other indications,
e.g. Crohn’s disease, have demonstrated that biologi-
cals do not exacerbate the toxicity of other therapies
used for psoriasis, such as methotrexate.48 Interim
results in small numbers of patients suggest that
alefacept can be safely combined with other psoriasis
therapies (e.g. high-potency topicals, methotrexate,
ciclosporin, oral retinoids and UVB).65 Thus, combi-
ning biologicals with other immunomodulating ther-
apies can be considered on a case-by-case basis,
particularly when tapering patients off current therap-
ies such as methotrexate or ciclosporin. Until appro-
priate studies have been conducted to confirm their
safety and efficacy, biological therapies themselves
should not be combined with each other. Combining
biologicals with topical therapies is anticipated to be
safe; therefore, topical therapies can be added if
necessary.
Long-term therapy
Consensus: Given the apparent lack of traditional end-
organ toxicity (e.g. nephrotoxicity or hepatotoxicity),
biologicals may he used for significant periods of time.
Data to date demonstrate that biological therapies are
capable of providing long-term disease control
(Table 4). While alefacept is not indicated for continu-
ous long-term administration, the remittive effects,
lasting up to 7 months in responders, provide patients
with long-term control. Multiple courses of alefacept
have been administered in a small number of patients
with apparent efficacy and safety.43 Efalizumab has
demonstrated sustained efficacy without increased
toxicity during continuous dosing of up to
24 months.42 As in rheumatoid arthritis and Crohn’s
disease, long-term administration of etanercept and
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long-term intermittent use of infliximab appear to be
feasible for psoriasis, though neither agent is currently
approved for such use in psoriasis. Data and experience
suggest that biologicals promise to provide psoriasis
patients with long-term control of their disease.
Impact on quality of life
Consensus: In addition to improving the physical signs
of psoriasis, there is ample evidence from large random-
ized, controlled trials to demonstrate that biological
therapies improve multiple facets of quality of life.
Patients demonstrated significant improvement in
QOL as determined by multiple measures, including
Dermatology QOL Scales, Short form 36 and Derma-
tology Life Quality Index (Table 4). Improvement on
these patient-reported scales reflects improved func-
tionality (e.g. ability to perform job or attend school),
decreased impact of treatment on daily living,
improved social relations, and a reduction in the
overall frequency and severity of psoriasis symptoms.
Importantly, the improvements achieved during short-
term administration (e.g. 12 weeks) were sustained
with extended dosing.44, 66
The new treatment paradigm: consensus guidance for
treatment of psoriasis
Consensus: Treatment of psoriasis no longer requires a
strict, step-wise approach; instead, decisions can be based on
patient presentation, disease severity and patient-specific
characteristics. Treatment decisions are based upon a
variety of factors, including the extent and site of
involvement, type of psoriasis, burden of disease and ⁄ or
disability, prior psoriasis treatments (including effective-
ness, cumulative doses if applicable, and tolerance), age
and life stages, pregnancy considerations, concomitant
illnesses or medications, extent of disability, the patient’s
goals and expectations from therapy, and the overall
convenience of the therapeutic regimen and the patient’s
ability to comply with the prescribed treatment.
For many clinicians, psoriasis management has
typically followed a progression in which patients fail
the previous step before treatment with a more
aggressive (and more toxic) therapy is initiated;
therefore, treatment considerations in psoriasis typic-
ally progress sequentially from topical therapies to
phototherapy and finally to systemic therapy.4, 20, 67
However, topical therapy may not be considered as
initial therapy in patients with severe psoriasis.
Current practice patterns using biologicals are
providing new support for the notion that psoriasis
management does not require a strict, step-wise
approach.
In 2003, the American Academy of Dermatology
developed a consensus statement for the treatment of
moderate to severe plaque psoriasis.68 According to
that statement, biological therapies can be considered
alongside current systemic therapies in patients who
are candidates for systemic therapy. Based on efficacy
and safety profiles, convenience and QOL improvement
achieved with biological therapies, it was agreed that
biologicals should be given equal consideration among
primary agents that are appropriate in patients who are
candidates for systemic therapy. Many of the partici-
pants favoured biological therapies over current sys-
temic agents for the treatment of chronic plaque
psoriasis in certain situations, based on available safety
data at this relatively early time in the clinical
experience with biologicals.
Our suggested approach for integrating biologicals
into clinical practice is illustrated in Figure 1. Various
instances in which biologicals should be considered,
from both patient and physician perspectives, are
outlined in Table 5. For example, in addition to
patients for whom topical therapies are ineffective or
impractical and who are candidates for or who have
failed or are intolerant to systemic therapy, there are
specific instances in which biological therapies are
likely to provide therapeutic benefit. Examples include
patients for whom current therapies are impractical,
patients who are concerned about safety (short- vs.
long-term safety), patients with recalcitrant psoriasis
or alternate psoriasis morphologies (as discussed
below), and patients who have a significant reduction
in QOL or who are physically incapacitated. In
addition to patient-related factors, physicians should
consider biologicals when they wish to prescribe a
single agent that can be safely administered, have
particular safety concerns or are considering utilising
biologicals in combination with acceptable agents.
Future applications
There is possibly an opportunity to treat forms of
psoriasis other than chronic plaque psoriasis, including
difficult-to-treat psoriasis, with biologicals. Published
data and case reports suggest that biologicals may be as
useful as current systemic therapies for recalcitrant
psoriasis,69 and other subtypes such as palmoplantar
pustulosis, erythrodermic psoriasis and pustular psori-
asis.70–74
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While cost must be considered an important factor in
treatment decisions, our discussions focused on clinical
and scientific aspects. It is important that dermatologists
advocate the best therapies possible and advise regula-
tory bodies and agencies regarding the value of such
therapies. This is of particular relevance in a chronic
disease such as psoriasis, which has significant QOL as
well as physical issues for patients.
Conclusions
Dermatologists need to familiarize themselves with these
new therapies, particularly as regards rationale, their
mechanisms of action, and most importantly, efficacy
and safety in the treatment of psoriasis. Furthermore,
dermatologists should have the opportunity to use and
prescribe biological therapies for their patients as their
colleagues in rheumatology and gastroenterology have
done for the past 5 years. Given the diverse morpholo-
gies and fluctuating nature of psoriasis, as well as the
psychosocial impact of the disease, dermatologists are in
a better position than other specialists to manage the
complexities of psoriasis on a long-term basis. Available
evidence shows that biological therapies provide short-
term, and perhaps offer long-term control of psoriasis,
coupled with improved safety, tolerability, convenience
and improvement in QOL. This is the beginning of an
exciting era for dermatologists and patients alike.
Biologicals appear to offer great promise in the day-to-
day and longer-term management of patients with
psoriasis and hopefully will allow the dermatology
Table 5. Consensus: instances where biological therapies should be
considered
Patient-related considerations
1 Patients for whom topical therapy is ineffective or impractical
2 Patients with plaque psoriasis who are candidates for
systemic therapy
3 Patients who have failed or are intolerant of current systemic
therapies
4 Patients for whom current systemic therapies are
contraindicated
5 Patients for whom current systemic therapies or phototherapy
is impractical (e.g. due to distance to phototherapy treatment
facility)
6 Patients with recalcitrant psoriasis
7 Patients with severe impairment of quality of life and ⁄ or
physical or psychosocial disability
8 Patients who are physically incapacitated (i.e. unable to use
topical or ultraviolet therapy)
Physician-related considerations
1 Case-based need for practical monotherapy options
2 Case-based need for a long-term therapeutic option
3 Particular safety concerns
4 Case-based requirements for biologicals in combination with
other psoriasis therapies, or transition with other psoriasis
therapies (this requires further study and may involve multiple
combinations)
















*Moderate to severe psoriasis is understood to be a disease for which systemic therapy is appropriate, A diagnosis of plaque psoriasis is typically
  based on characteristic appearance; skin biopsies are rarely necessary given expert dermatological care.103,104 Given the variable course of psoriasis
  in terms of location, extent of involvement and associated symptoms,105 continuity of care is important in psoriasis management. Definitions of psoriasis
  severity have not been standardized,105 and traditional measures of disease severity are based upon the extent of body surface area involvement.
  However, such measures fail to consider a variety of factors, such as severe but localized involvement, location of disease (e.g. face, palms or soles and 
  genitals), associated symptoms and impact on quality of life.105,106 Thus, disease severity is considered on a case-by-case basis.
†Each of the agents within each category may be an equivalent option, based on disease- and patient-specific factors. Combinations of various treatment
 options are possible; however, patient and drug-specific factors must be considered for each case.
‡Reflects agents with published data to support their use in psoriasis; as favourable data evolve for additional agents, they would be appropriate 
  for consideration.
Figure 1. Consensus: incorporating biological therapies into clinical practice.103–106
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profession to take its rightful place alongside other
medical subspecialties using biological therapy.
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